Technology evaluation: APC-80200, Dendreon.

@article{Rice2002TechnologyEA,
  title={Technology evaluation: APC-80200, Dendreon.},
  author={Alison M Rice and Derek Hart},
  journal={Current opinion in molecular therapeutics},
  year={2002},
  volume={4 5},
  pages={523-7}
}
APC-80200 (Mylovenge) has been developed for the treatment of B-cell malignancies and is currently in phase II clinical trials as a therapeutic vaccine for patients with advanced multiple myeloma. This vaccine candidate appears to be of particular benefit in patients who have received high-dose chemotherapy to reduce tumor load following stem cell rescue… CONTINUE READING